In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.

[1]  F. García-Contreras,et al.  Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1. , 2006, Archives of medical research.

[2]  K J Brodbeck,et al.  Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Gilson Khang,et al.  Thermosensitive poly(organophosphazene) hydrogels for a controlled drug delivery. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  T. Saibara,et al.  Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. , 2002, International immunopharmacology.

[5]  Q. Yao,et al.  Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes. , 2007, Immunology letters.

[6]  Ying-zhe Fan,et al.  Thymosin α1 suppresses proliferation and induces apoptosis in human leukemia cell lines , 2006, Peptides.

[7]  M. Gekle,et al.  Cytotoxicity, metabolism and cellular uptake of the mycotoxin deoxynivalenol in human proximal tubule cells and lung fibroblasts in primary culture. , 2007, Toxicology.

[8]  R. Bodmeier,et al.  Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[9]  A. Xu,et al.  Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration , 2008, Acta Pharmacologica Sinica.

[10]  W. Herrmann,et al.  Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers. , 1999, International journal of clinical pharmacology and therapeutics.

[11]  Jagdish Singh,et al.  In vitro release of insulin and biocompatibility of in situ forming gel systems. , 2005, International journal of pharmaceutics.

[12]  G. Rasi,et al.  Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer , 2003 .

[13]  A. G. Ding,et al.  Rescue of SCID murine ischemic hindlimbs with pH-modified rhbFGF/poly(DL-lactic-co-glycolic acid) implants. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[14]  A. Sodhi,et al.  Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice. , 2002, Immunology letters.

[15]  Wei Zhao,et al.  Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. , 2008, Antiviral research.

[16]  A. Dash,et al.  A novel in situ gel for sustained drug delivery and targeting. , 2004, International journal of pharmaceutics.

[17]  R. Zheng,et al.  Antioxidant activities of Sophora subprosrate polysaccharide in immunosuppressed mice. , 2007, International immunopharmacology.

[18]  Mohammad Erfan,et al.  Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. , 2009, Journal of pharmaceutical sciences.

[19]  A. Ruiz-Bravo,et al.  A probiotic strain of Lactobacillus plantarum stimulates lymphocyte responses in immunologically intact and immunocompromised mice. , 2007, International journal of food microbiology.

[20]  W. Loo,et al.  Thymosin alpha 1 provides short-term and long-term benefits in the reimplantation of avulsed teeth: a double-blind randomized control pilot study. , 2008, The American journal of emergency medicine.

[21]  P. D. Graham,et al.  Phase inversion dynamics of PLGA solutions related to drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[22]  G. Rasi,et al.  Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. , 2000, International journal of immunopharmacology.

[23]  T. Moody,et al.  Thymosin α1 inhibits mammary carcinogenesis in Fisher rats , 2002, Peptides.

[24]  A. Knutsen,et al.  Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. , 1999, International journal of immunopharmacology.

[25]  A Hatefi,et al.  Biodegradable injectable in situ forming drug delivery systems. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[26]  A. Mikos,et al.  Injectable biodegradable polymer composites based on poly(propylene fumarate) crosslinked with poly(ethylene glycol)-dimethacrylate. , 2000, Biomaterials.

[27]  H. Mirzadeh,et al.  Influence of poly (lactide-co-glycolide) type and gamma irradiation on the betamethasone acetate release from the in situ forming systems. , 2009, Current drug delivery.

[28]  H. Moghimi,et al.  FORMULATION OF AN INJECTABLE IMPLANT FOR PEPTIDE DELIVERY AND MECHANISTIC STUDY OF THE EFFECT OF POLYMER MOLECULAR WEIGHT ON ITS RELEASE BEHAVIOR , 2006 .

[29]  H. Yao,et al.  The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells in the absence or presence of tumor necrosis factor-alpha. , 2004, International immunopharmacology.

[30]  P. Messersmith,et al.  Triggered release of calcium from lipid vesicles: a bioinspired strategy for rapid gelation of polysaccharide and protein hydrogels. , 2001, Biomaterials.

[31]  H. Ravivarapu,et al.  Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. , 2000, International journal of pharmaceutics.